** Biotech firm Elicio Therapeutics' ELTX.O shares fall 14% to an over 2-month low of $6.71
** ELTX now expects mid-stage study data of its lead experimental vaccine, ELI-002, in Q3 2025 vs. previous expectation of H1 2025
** Co is testing vaccine against certain types of solid tumors that are caused by mutations in the KRAS gene, which are common in pancreatic, colorectal, and non-small cell lung cancers
** ELTX's net loss also widens in 2024 compared with 2023
** As of last close, ELTX has risen 2.5% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。